Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year

MPM BioImpact fully exited its position in Crinetics Pharmaceuticals during the third quarter, a move disclosed in the fund’s November 14 SEC filing. The transaction reduced assets by approximately $12.3 million.According to a filing with the Securities and Exchange Commission dated November 14, MPM BioImpact sold its entire holding of 428,975 shares in Crinetics Pharmaceuticals (NASDAQ:CRNX) in the third quarter. The estimated transaction value was $12.3 million based on quarterly average prices. The position represented 2.1% of assets under management in the previous quarter.Top holdings after the filing:  Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool